Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Size, Industry Analysis Report, Regional Outlook, Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Report ID: GMI3038

Summary Methodology

Paroxysmal nocturnal hemoglobinuria (PNH) treatment market size is expected to grow significantly from 2018 to 2024.

Paroxysmal nocturnal hemoglobinuria (PNH) treatment market will experience lucrative growth over the coming years due to increasing incidences of bone marrow and blood related disorders. According to National Organization for Rare Diseases (NORD), around 0.5-1.5 per million general population suffer from PNH.

Significant investment towards development of novel therapeutic compounds to treat paroxysmal nocturnal hemoglobinuria (PNH) should accelerate business growth. Apellis Pharmaceuticals, a clinical-stage biopharmaceutical company has currently commenced with PEGASUS phase 3 trial for assessing efficacy and safety of APL-2 therapy in PNH patients.

Associations such as The Canadian Association of PNH Patients (PNHCA) functions to create awareness regarding the disorder should support industry growing during the forecast period. As per the PNHCA, presently 10 organizations globally are conducting clinical trials to develop effective treatment for Paroxysmal nocturnal hemoglobinuria (PNH), thereby fueling industry growth. However, adverse effects associated with currently available treatments and lack of reimbursement policies in developing countries will hinder industry expansion to certain extent over the coming years.

Based on treatment, the industry is bifurcated into stem cell transplantation, blood transfusion and medication.  Medication segment will experience lucrative growth during the forecast period owing to increasing investment towards developing effective treatment for PNH as well as high adoption of Soliris (eculizumab) to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.

Development of novel treatments including recombinant proteins, monoclonal antibodies, and cyclic peptides especially in developed countries of North America and Europe should drive industry growth. Pharmaceutical and biotech companies’ end-user segment is estimated to grow significantly during the forecast period due to high investment made by companies for developing superior treatment for PNH.

Growing demand for novel therapeutics, strong product pipeline and rising healthcare expenditure will drive North America paroxysmal nocturnal hemoglobinuria treatment market. Increasing incidences of blood related disorders in the country will positively impact business growth. Around 400-500 people annually are diagnosed with PNH in the U.S.

Development of healthcare system, growing disposable income coupled with unmet need of proper treatment for paroxysmal nocturnal hemoglobinuria should drive Asia Pacific market during the forecast period. Growing awareness as well as rising number of people suffering from conditions related with blood and bone marrow should positively affect Asia Pacific paroxysmal nocturnal hemoglobinuria treatment industry growth.

Major industry players such as Roche, Akari Therapeutics, Alexion Pharmaceuticals, Ra Pharmaceuticals, Novartis Pharmaceuticals, Alnylam, Apellis Pharmaceuticals, Achillion Pharmaceuticals, and Regeneron Pharmaceuticals compete in paroxysmal nocturnal hemoglobinuria (PNH) treatment market. These companies are focused towards developing effective treatment for PNH for which the companies are collaborating with research institutes and laboratories.

Paroxysmal nocturnal hemoglobinuria (PNH) treatment market, by treatment, 2013-2024 (USD Million)

  • Stem cell transplantation
  • Blood transfusion
  • Medication

Paroxysmal nocturnal hemoglobinuria (PNH) treatment market, by end-user, 2013-2024 (USD Million)

  • Hospitals
  • Clinics
  • Pharmaceutical and biotech companies
  • Academic & research institutes
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
  • Latin America
    • Mexico
    • Brazil
  • Middle East and Africa
    • Saudi Arabia
    • South Africa

Company Profiles:

  • Roche
  • Akari Therapeutics
  • Alexion Pharmaceuticals
  • Ra Pharmaceuticals
  • Novartis Pharmaceuticals
  • Alnylam
  • Apellis Pharmaceuticals
  • Achillion Pharmaceuticals
  • Regeneron Pharmaceuticals

What Information does this report contain?

Historical data coverage: 2013 to 2015; Growth Projections: 2016 to 2026.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Customize this Report

Pre Book Now

Need a Discount? Get in touch with us for special pricing

Request Discount

Our Market Research Reports Include:

  • Market snapshot
  • Market Segmentation
  • Value Chain Analysis
  • Growth Dynamics
  • Potential Market Opportunities
  • Regulatory Overview
  • Technology Evolution
  • Innovation & Sustainability

 Connect with our sales team

Benefits of Association

Data Coverage & Quality

GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.

Client Trust & Security

GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.

Customer Service

Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.

GMIPulse, our report store

We have introduced ‘GMIPulse’, which is our report store; designed to offer clients a one-stop platform for all market research and business intelligence requirements. Clients can access reports, presentations, raw data excel sheets as well as detailed company profiles. GMIPulse allows you to track relevant industries and stay informed with latest innovation, competitive and regulatory developments to help design strategic framework.

Chat with us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X